Head-to-head evidence
Canagliflozin vs THR-1442
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: October 2026 · NCT07711171 (registry estimate)
THR-1442
Developed by Newsoara Biopharma
NCT05369078 · Phase 1 · status unknown
This was a small, non-randomized, unblinded study in healthy volunteers with no placebo or comparator arm, designed only to characterize safety and drug levels. Results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · THR-1442's landscape